title: External validity of trials should be taken into account before asthma drug candidates reach market authorisation.
authors.affiliation: Division of Medicine, University College London, London WC1E 6BT, UK. Electronic address: orestis.briasoulis.15@ucl.ac.uk.
authors.forename: Orestis
authors.initials: O
authors.lastname: Briasoulis
authors.affiliation: Division of Medicine, University College London, London WC1E 6BT, UK.
authors.forename: Ross
authors.initials: R
authors.lastname: Breckenridge
authors.affiliation: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London WC1E 6BT, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Nunn
mesh_terms: D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001249:Asthma / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005260:Female; D006801:Humans; D008297:Male; D020380:Needs Assessment; D018579:Patient Selection; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D014481:United States
chemical_list: D018927:Anti-Asthmatic Agents